Ambrx Biopharma Inc. Appoints Daniel O'Connor as Chief Executive Officer Seite 1
01.11.2022 - Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Daniel O’Connor as Chief ... Seite 1